In a report published on Wednesday, the rating went from a "buy" to a "hold".
Curis Price Performance
Trading was down $0.02 at midday on Wednesday. The stock reached $0.81. The company's shares changed hands in a volume that was 218 941 compared to the average of 427 379. Curis's 1 year low is $0.47, and its 1 year high is $1.77. The 50-day moving-average of the company is $0.84, and its 200-day moving-average is $0.71. The last time the company released its quarterly earnings was on Thursday, 4th May. The biotechnology firm reported ($0.12) in earnings per share during the first quarter of the year, falling short by ($0.01) of the consensus estimate ($0.11). Revenue for the quarter was $2.30m, which is lower than the consensus estimate ($2.49m). Curis's negative return on equity was 103.76%, and its negative net margin was 501.08%. In the same period of the prior year, the company earned ($0.18) per share. Analysts expect Curis to post a -0.47 earnings per share for the current fiscal period.
Curis: Institutional investors weigh in
Recently, several institutional investors made changes to the positions they hold in CRIS. HRT Financial LP purchased a new Curis position during the fourth quarter, valued at approximately $29,000. Engineers Gate Manager LP purchased a new position in Curis shares during the first quarter, valued at approximately $32,000. UBS Group AG increased its holdings of Curis by 183.6 % during the third quarter. UBS Group AG owns 51 332 shares in the biotechnology company valued at $36,000, after purchasing an additional 33 231 shares. Virtu Financial LLC purchased a new Curis position valued at $51,000 in the fourth quarter. Bank of Montreal Can also bought a stake in Curis during the second quarter, valued at $59,000. Institutional investors hold 29.67% the stock of Curis.
Curis Company Profile
Curis, Inc., a biotechnology firm, is engaged in the discovery and the development of drug candidate for the treatment of cancer in humans in the United States. Emavusertib is a small molecule oral drug candidate that is currently in a Phase 1 clinical trial to treat non-Hodgkin lymphomas and acute myeloid Leukemia. It also has CI-8993 which was designed to block the V-domain Ig suppressor for T cell activation.
MarketBeat.com offers a FREE daily email newsletter